- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
89bio Inc.
Headquarters: San Francisco, CA, United States of America
Website: https://www.89bio.com/
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Rohan Palekar, MBA
Number Of Employees: 93
Enterprise Value: $416,462,274
PE Ratio: -2.38
Exchange/Ticker 1: NASDAQ:ETNB
Exchange/Ticker 2: N/A
Latest Market Cap: $1,194,148,992
BioCentury | Feb 19, 2025
Finance
China competition. Plus: FDA firings and biotech IPOs
Why U.S. biotechs should embrace the challenge from China biotech
BioCentury | Feb 1, 2025
Finance
Metsera, Maze land on NASDAQ as IPO queue grows
BioCentury’s Public Equity Report: MASH data drive follow-ons for Akero, 89bio
BioCentury | Jan 28, 2025
Product Development
Patience pays off for Akero in MASH
After a stumble in 2023, FGF21 agonist demonstrates fibrosis improvement in cirrhosis patients
BioCentury | Nov 15, 2024
Finance
Syncona building Slingshot incubator; Trace launches with $101M
BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
BioCentury | Sep 17, 2024
Management Tracks
Peter Maag resigns as Kyverna CEO
Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more
BioCentury | Aug 9, 2024
Management Tracks
A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element
Plus: Sarena becomes COO of 89bio
BioCentury | Mar 14, 2024
Regulation
Madrigal’s MASH drug is approved, now it’s time to build the market
FDA approves Rezdiffra as first MASH therapy
BioCentury | Mar 6, 2024
Product Development
Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks
Plus: Novo positions Ozempic to add CKD to label and updates from Apogee, RegenxBio, Ironwood
BioCentury | Feb 6, 2024
Product Development
Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more
Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM
BioCentury | Oct 10, 2023
Product Development
Akero’s NASH readout spreads worries to others in class
Despite miss on fibrosis endpoint, biotech touts strong performance on disease resolution, says totality of data support Phase III start
Items per page:
1 - 10 of 39